Almirall has completed the decentralised European regulatory procedure for efinaconazole, a triazole antifungal substance ...

Having been in development by Almirall and Eli Lilly and Company for moderate to severe AD, recent findings from a phase 3 trial for the first time have shown year-long (52-week) management of ...

Almirall has licensed an interleukin-2 (IL-2) drug from China's Simcere Pharma, joining the ranks of companies looking at blocking the cytokine as a way to treat autoimmune diseases.

BARCELONA, Spain--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its participation in the 33rd Congress of the European ...

Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology announced today the successful ...

An interim analysis from a long-term open-label extension study has underlined the clinical efficacy and safety of ...

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United ...

Partner Almirall makes progress following the late 2023 launch in Germany Eli Lilly's partner Almirall is making progress in Europe following the late 2023 approval by the EMA and the December ...

With the addition of this treatment, Almirall enhances its European medical dermatology portfolio and reaffirms its commitment to people living with skin infections and dermatologists by providing ...

Almirall has completed the decentralised European regulatory procedure for efinaconazole, a triazole antifungal substance with the trade name Jublia, to treat onychomycosis. This is a significant ...

New clinical data on Almirall’s biologics portfolio demonstrates further opportunities to positively impact patients and the medical community New data to be presented on tildrakizumab for the ...

Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology announced today the successful completion of the decentralized regulatory procedure in Europe for ...